IGF2 and adrenal cortex carcinoma: Based on preclinical data above showing that 90% of ACC overexpressed IGF2 and the inhibition of IGF2/IGF1R was effective in vivo, several clinical trials were conducted using monoclonal antibodies (cixutumumab and figitumumab) and a small molecule inhibitor (linsitinib).